Literature DB >> 33277927

Drug repurposing approach to combating coronavirus: Potential drugs and drug targets.

Jimin Xu1, Yu Xue1, Richard Zhou1, Pei-Yong Shi2, Hongmin Li3,4, Jia Zhou1.   

Abstract

In the past two decades, three highly pathogenic human coronaviruses severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus, and, recently, SARS-CoV-2, have caused pandemics of severe acute respiratory diseases with alarming morbidity and mortality. Due to the lack of specific anti-CoV therapies, the ongoing pandemic of coronavirus disease 2019 (COVID-19) poses a great challenge to clinical management and highlights an urgent need for effective interventions. Drug repurposing is a rapid and feasible strategy to identify effective drugs for combating this deadly infection. In this review, we summarize the therapeutic CoV targets, focus on the existing small molecule drugs that have the potential to be repurposed for existing and emerging CoV infections of the future, and discuss the clinical progress of developing small molecule drugs for COVID-19.
© 2020 Wiley Periodicals LLC.

Entities:  

Keywords:  COVID-19; MERS-CoV; SARS-CoV; SARS-CoV-2; anti-CoV; coronavirus; drug repurposing; drug targets; small molecule drugs

Mesh:

Substances:

Year:  2020        PMID: 33277927      PMCID: PMC8044022          DOI: 10.1002/med.21763

Source DB:  PubMed          Journal:  Med Res Rev        ISSN: 0198-6325            Impact factor:   12.944


  340 in total

Review 1.  Ribavirin for the treatment of chronic hepatitis C virus infection: a review of the proposed mechanisms of action.

Authors:  Jan Paeshuyse; Kai Dallmeier; Johan Neyts
Journal:  Curr Opin Virol       Date:  2011-11-29       Impact factor: 7.090

2.  Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection.

Authors:  Julie Dyall; Christopher M Coleman; Brit J Hart; Thiagarajan Venkataraman; Michael R Holbrook; Jason Kindrachuk; Reed F Johnson; Gene G Olinger; Peter B Jahrling; Monique Laidlaw; Lisa M Johansen; Calli M Lear-Rooney; Pamela J Glass; Lisa E Hensley; Matthew B Frieman
Journal:  Antimicrob Agents Chemother       Date:  2014-05-19       Impact factor: 5.191

3.  Functional studies indicate amantadine binds to the pore of the influenza A virus M2 proton-selective ion channel.

Authors:  Xianghong Jing; Chunlong Ma; Yuki Ohigashi; Fernando A Oliveira; Theodore S Jardetzky; Lawrence H Pinto; Robert A Lamb
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-31       Impact factor: 11.205

Review 4.  Cytochrome P450 of fungi: primary target for azole antifungal agents.

Authors:  Y Yoshida
Journal:  Curr Top Med Mycol       Date:  1988

5.  Characteristics of arbidol-resistant mutants of influenza virus: implications for the mechanism of anti-influenza action of arbidol.

Authors:  Irina A Leneva; Rupert J Russell; Yury S Boriskin; Alan J Hay
Journal:  Antiviral Res       Date:  2008-11-24       Impact factor: 5.970

6.  SARS-CoV-2 E protein is a potential ion channel that can be inhibited by Gliclazide and Memantine.

Authors:  Prabhat Pratap Singh Tomar; Isaiah T Arkin
Journal:  Biochem Biophys Res Commun       Date:  2020-06-20       Impact factor: 3.575

7.  A pneumonia outbreak associated with a new coronavirus of probable bat origin.

Authors:  Peng Zhou; Xing-Lou Yang; Xian-Guang Wang; Ben Hu; Lei Zhang; Wei Zhang; Hao-Rui Si; Yan Zhu; Bei Li; Chao-Lin Huang; Hui-Dong Chen; Jing Chen; Yun Luo; Hua Guo; Ren-Di Jiang; Mei-Qin Liu; Ying Chen; Xu-Rui Shen; Xi Wang; Xiao-Shuang Zheng; Kai Zhao; Quan-Jiao Chen; Fei Deng; Lin-Lin Liu; Bing Yan; Fa-Xian Zhan; Yan-Yi Wang; Geng-Fu Xiao; Zheng-Li Shi
Journal:  Nature       Date:  2020-02-03       Impact factor: 69.504

8.  Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study.

Authors:  Chantal B E M Reusken; Bart L Haagmans; Marcel A Müller; Carlos Gutierrez; Gert-Jan Godeke; Benjamin Meyer; Doreen Muth; V Stalin Raj; Laura Smits-De Vries; Victor M Corman; Jan-Felix Drexler; Saskia L Smits; Yasmin E El Tahir; Rita De Sousa; Janko van Beek; Norbert Nowotny; Kees van Maanen; Ezequiel Hidalgo-Hermoso; Berend-Jan Bosch; Peter Rottier; Albert Osterhaus; Christian Gortázar-Schmidt; Christian Drosten; Marion P G Koopmans
Journal:  Lancet Infect Dis       Date:  2013-08-09       Impact factor: 25.071

9.  A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster.

Authors:  Jasper Fuk-Woo Chan; Shuofeng Yuan; Kin-Hang Kok; Kelvin Kai-Wang To; Hin Chu; Jin Yang; Fanfan Xing; Jieling Liu; Cyril Chik-Yan Yip; Rosana Wing-Shan Poon; Hoi-Wah Tsoi; Simon Kam-Fai Lo; Kwok-Hung Chan; Vincent Kwok-Man Poon; Wan-Mui Chan; Jonathan Daniel Ip; Jian-Piao Cai; Vincent Chi-Chung Cheng; Honglin Chen; Christopher Kim-Ming Hui; Kwok-Yung Yuen
Journal:  Lancet       Date:  2020-01-24       Impact factor: 79.321

10.  Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention.

Authors:  Zunyou Wu; Jennifer M McGoogan
Journal:  JAMA       Date:  2020-04-07       Impact factor: 56.272

View more
  11 in total

Review 1.  Drug Repurposing for COVID-19: A Review and a Novel Strategy to Identify New Targets and Potential Drug Candidates.

Authors:  Liliana Rodrigues; Renata Bento Cunha; Tatiana Vassilevskaia; Miguel Viveiros; Celso Cunha
Journal:  Molecules       Date:  2022-04-23       Impact factor: 4.927

2.  Conserved coronavirus proteins as targets of broad-spectrum antivirals.

Authors:  Cleber C Melo-Filho; Tesia Bobrowski; Holli-Joi Martin; Zoe Sessions; Konstantin I Popov; Nathaniel J Moorman; Ralph S Baric; Eugene N Muratov; Alexander Tropsha
Journal:  Antiviral Res       Date:  2022-06-09       Impact factor: 10.103

3.  Substituted N-(4-amino-2-chlorophenyl)-5-chloro-2-hydroxybenzamide analogues potently inhibit respiratory syncytial virus (RSV) replication and RSV infection-associated inflammatory responses.

Authors:  Jimin Xu; Wenzhe Wu; Haiying Chen; Yu Xue; Xiaoyong Bao; Jia Zhou
Journal:  Bioorg Med Chem       Date:  2021-04-18       Impact factor: 3.461

Review 4.  Resources and computational strategies to advance small molecule SARS-CoV-2 discovery: lessons from the pandemic and preparing for future health crises.

Authors:  Natesh Singh; Bruno O Villoutreix
Journal:  Comput Struct Biotechnol J       Date:  2021-04-26       Impact factor: 7.271

5.  Chemoinformatic Analysis of Psychotropic and Antihistaminic Drugs in the Light of Experimental Anti-SARS-CoV-2 Activities.

Authors:  Bruno O Villoutreix; Rajagopal Krishnamoorthy; Ryad Tamouza; Marion Leboyer; Philippe Beaune
Journal:  Adv Appl Bioinform Chem       Date:  2021-04-12

Review 6.  A Review of the Current Landscape of SARS-CoV-2 Main Protease Inhibitors: Have We Hit the Bullseye Yet?

Authors:  Guillem Macip; Pol Garcia-Segura; Júlia Mestres-Truyol; Bryan Saldivar-Espinoza; Gerard Pujadas; Santiago Garcia-Vallvé
Journal:  Int J Mol Sci       Date:  2021-12-27       Impact factor: 5.923

7.  COVIDrugNet: a network-based web tool to investigate the drugs currently in clinical trial to contrast COVID-19.

Authors:  Luca Menestrina; Chiara Cabrelle; Maurizio Recanatini
Journal:  Sci Rep       Date:  2021-09-30       Impact factor: 4.379

8.  Indomethacin-based PROTACs as pan-coronavirus antiviral agents.

Authors:  Jenny Desantis; Beatrice Mercorelli; Marta Celegato; Federico Croci; Alessandro Bazzacco; Massimo Baroni; Lydia Siragusa; Gabriele Cruciani; Arianna Loregian; Laura Goracci
Journal:  Eur J Med Chem       Date:  2021-09-04       Impact factor: 6.514

Review 9.  Approaches to the Potential Therapy of COVID-19: A General Overview from the Medicinal Chemistry Perspective.

Authors:  J Carlos Menéndez
Journal:  Molecules       Date:  2022-01-20       Impact factor: 4.411

Review 10.  Haste makes waste: A critical review of docking-based virtual screening in drug repurposing for SARS-CoV-2 main protease (M-pro) inhibition.

Authors:  Guillem Macip; Pol Garcia-Segura; Júlia Mestres-Truyol; Bryan Saldivar-Espinoza; María José Ojeda-Montes; Aleix Gimeno; Adrià Cereto-Massagué; Santiago Garcia-Vallvé; Gerard Pujadas
Journal:  Med Res Rev       Date:  2021-10-26       Impact factor: 12.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.